Study to Evaluate D-1553 in Subjects With Lung Cancer
This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic NSCLC with KRasG12C mutation
NSCLC
DRUG: D-1553
Subject incidence of Dose-limiting toxicities (DLT), Subject incidence of Dose-limiting toxicities (DLT), through out the DLT period, approximately 21 days|Number of subjects participants with adverse events, Number of subjects participants with adverse events, Through study completion, approximately 3 years|antitumor activity of D-1553 in subjects with advanced or metastatic NSCLC with KRASG12C mutation, Overall Response Rate (ORR, Complete Response \[CR\] + Partial Response \[PR\]), Through study completion, approximately 3 years
Plasma concentration of D-1553, Plasma concentration of D-1553 as a single agent in subjects with advanced or metastatic NSCLC with KRas G12C mutation, approximately 6 months
This is a phase 1/2, open label study of D-1553 single agent treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic NSCLC with KRasG12C mutation